目的 探讨来曲唑在老年绝经后乳腺癌新辅助内分泌治疗中的近期疗效,耐受性及与临床病理因素的相关性.方法 对58例绝经后激素受体阳性的乳腺癌患者进行来曲唑新辅助内分泌治疗,以他莫昔芬新辅助内分泌治疗为对照组.结果 来曲唑组临床疗效显著优于他莫昔芬组(P＜0.05).来曲唑组临床分期晚,ER及PR均阳性的有效率高,与HER-2表达无关.他莫昔芬组HER-2阳性的有效率低.2组治疗前后Ki-67水平均显著下降,有统计学意义(P＜0.05).2组未出现明显不良反应.结论 绝经后、激素受体阳性的乳腺癌选择来曲唑新辅助内分泌治疗安全,有效,尤其适合有合并症的老年体弱者.%Objective To Evaluate the efficacy and tolerability of letrozole in neoadjuvant endocrine therapy of elderly postmenopausal breast cancer patients and its correlation with clinicopathologic factors. Methods 58 cases of postmenopausal hormone receptor-positive breast cancer treated with letrozole,compared with tamoxifen in neoadjuvant endocrine therapy. Results Letrozole was more effective than tamoxifen in clinical response rates ( P < 0. 05 ). Letrozole response rate was significantly higher in late clinical stage or ER and PR positive patients and had nothing to do with HER-2 expression. Tamoxifen was significantly less effective in HER2 + tumors. The expression of Ki-67 decreased remarkably after treatment of letrozol or tamoxifen. They were well-torerated in the neoadjuvant setting. Conclusion Neoadjuvant endocrine therapy with letrozole for postmenopausal hormone receptor-positive breast cancer is effective and safe, especially for frail elderly women concomitant with some serious diseases.
展开▼
